Navigation Links
Sirion Therapeutics Acquires Worldwide License to Develop New Treatment for Ocular Diseases
Date:2/20/2008

post- operative inflammation and uveitis; ganciclovir, a topical antiviral for herpetic keratitis; cyclosporine, a topical immunomodulator for dry eye; and fenretinide, a first-in-class oral vitamin A binding protein antagonist for geographic atrophy associated with dry AMD. In addition, Sirion has preclinical programs in back of the eye diseases and allergy. For more information, please visit http://www.siriontherapeutics.com .

About Bridge Pharma, Inc.

Bridge Pharma, Inc. is a privately held pharmaceutical research and development company located in Sarasota, FL. Bridge Pharma was founded in 1996 by Dr. Gunnar Aberg, currently CEO. In addition to the current license with Sirion Therapeutics, Bridge has out-licensed internally developed drugs for growth promotion, heaves in horses, obesity, pain, over-active bladder and urinary incontinence. Bridge is committed to the discovery, research and development of NCEs that provide therapeutic treatment for unmet medical needs.

Forward-Looking Statements

This press release contains forward-looking statements and information about Sirion Therapeutics, Inc.'s and Bridge Pharma Inc.'s business and products. These forward-looking statements are only business forecasts. Actual results may differ from the results anticipated, expressed or implied by these forward-looking statements and are dependent upon, among other things, drug applications and regulatory authorizations.


'/>"/>
SOURCE Sirion Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sirion Therapeutics Supports Ophthalmic Education
2. Ocera Therapeutics Closes $35.5 Million Series C Financing
3. Amsterdam Molecular Therapeutics Reports Full Year Results 2007
4. United Therapeutics Reports Fourth Quarter and Annual 2007 Financial Results
5. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
6. Cell Therapeutics, Inc. (CTI) Announces Cancellation of Approximately $9.1 Million of Existing Notes due 2008
7. PeriCor Therapeutics Appoints K. Tucker Andersen to Board of Directors
8. United Therapeutics to Announce Fourth Quarter and Annual 2007 Financial Results Before Market Open on Tuesday, February 19, 2008
9. Nektar Announces Restructuring to Complete Its Transition to a Therapeutics Drug Development Organization
10. Mersana Therapeutics, Inc. Appoints Chief Scientific Officer, Timothy B. Lowinger, Ph.D.
11. Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operations in 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... IRVINE, CA (PRWEB) , ... August 28, 2015 ... ... leader in Personalized Medicine, presented two studies at the International Spine Intervention ... on July 28th, 2015 through to August 1st, 2015. With a focus on ...
(Date:8/28/2015)... ... 2015 , ... Since the initial launch of FireflySci Inc. (FFS) in early 2015, the company ... Images such as the Fonz in a lab coat and Large Marge have been ... spectroscopy field. , FireflySci is proud to be the only cuvette manufacturer is ...
(Date:8/27/2015)... 2015 /PRNewswire/ - Portage Biotech Inc. ("Portage") (OTC ... Pharmaceutical Holding Company Limited (Biohaven), announced today that ... of BHV-0223, a glutamate modulating agent. Biohaven filed ... recently obtained clearance from the U.S. Food and ... Portage holds 54% equity interest in Biohaven, a ...
(Date:8/27/2015)... 27, 2015 HUYA Bioscience International (HUYA) today announced ... Japan Society of HTLV-1, held this week at the ... of the Society is to promote research on HTLV-1 ... medical technology and research related to these fields to ... "HUYA is proud to support this prestigious conference," said ...
Breaking Biology Technology:Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 2Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 3Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 4Cuvette Manufacturer FireflySci Launches Back to School Deals with Complimentary Shipping On All Orders 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4
... Imaging,Diagnostic Systems, Inc., (OTC Bulletin Board: ... systems, will exhibit CT Laser Mammography (CTLM(R)),technology ... Cancer,Conference, March 1-5, in Las Vegas, Nevada. ... (Logo: http://www.newscom.com/cgi-bin/prnh/20040412/IMDSLOGO ), "Attending ...
... SAN DIEGO, Feb. 27 NuVasive, Inc. (Nasdaq:,NUVA), a ... surgical treatments for the spine, announced today,that Kevin O,Boyle, ... present at the Canaccord Adams, Small-Cap Orthopedics,Conference at The ... on Tuesday, March 4, 2008 at 8:10 a.m. PT., ...
... Ocera Therapeutics, a,biopharmaceutical company focused on the ... a broad range of,gastrointestinal and liver diseases, announced ... company as Chief Medical Officer. Prior to joining,Ocera, ... Officer and Vice,President of Clinical Affairs at Napo ...
Cached Biology Technology:CT Laser Mammography Technology to be Featured at Interdisciplinary Breast Cancer Conference 2NuVasive to Present at Canaccord Adams' Small-Cap Orthopedics Conference 2NuVasive to Present at Canaccord Adams' Small-Cap Orthopedics Conference 3M. Scott Harris, M.D., Joins Ocera Therapeutics, Inc., as Chief Medical Officer 2
(Date:8/5/2015)... According to a new market research report, ... (BFSI, Airport, IT & Telecom, Utilities, Education, Defense & ... published by MarketsandMarkets, defines and segments the Physical Identity ... global PIAM Market is estimated to grow from $272.2 ... a CAGR of 14.9 % from 2014 to 2019. ...
(Date:8/3/2015)... 2015 Synaptics, Inc. (Nasdaq: SYNA ), ... that members of the executive management team will present ... Technology Leadership Forum on Tuesday, August 11, 2015 at ... at the Sonnenalp Resort in Vail, CO. ... forward-looking information. An audio webcast of the event will ...
(Date:7/31/2015)... 31 de julio de 2015 La 10 th ... celebrará por medio de BGI del 22 al 25 de octubre ... Este año, la conferencia celebra su décimo aniversario. ... convertido en una de las reuniones anuales más influyentes del ... las reuniones más dinámicas, entusiastas y mejores a nivel científico. ...
Breaking Biology News(10 mins):Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3
... major research findings at the 11th International Coral Reef Symposium ... African Dust Poses Threat to Coral Reefs and Human ... Caribbean and the Americas may be a threat to marine ... study by researchers with the U.S. Geological Survey, Oregon State ...
... Researchers from Harvard Medical School and Brandeis University have ... what types of genes are necessary for brain development. ... are published July 4th in the open-access journal PLoS ... sequencing of entire genomes and the discovery of RNA-interference ...
... the biggest challenges facing humanity is to halt the destruction ... task that must be urgently addressed and in which we ... is our duty to do all we can for the ... researchers Harold Mooney and Peter Raven, regarded as the architects ...
Cached Biology News:The good, the bad and the smelly: USGS at the 2008 Coral Reef Symposium 2The good, the bad and the smelly: USGS at the 2008 Coral Reef Symposium 3The good, the bad and the smelly: USGS at the 2008 Coral Reef Symposium 4The good, the bad and the smelly: USGS at the 2008 Coral Reef Symposium 5The good, the bad and the smelly: USGS at the 2008 Coral Reef Symposium 6The good, the bad and the smelly: USGS at the 2008 Coral Reef Symposium 7The good, the bad and the smelly: USGS at the 2008 Coral Reef Symposium 8The good, the bad and the smelly: USGS at the 2008 Coral Reef Symposium 9Researchers reveal types of genes necessary for brain development 2BBVA Foundation Awards for Biodiversity Conservation 2BBVA Foundation Awards for Biodiversity Conservation 3BBVA Foundation Awards for Biodiversity Conservation 4
NATIVE, ENZYME PORCINE TRYPSIN...
G-Protein Coupled Receptor Assay, For 500 assays. SPA. Category: Drug Screening & Cellular Assays, Assays ....
EDTA, disodium salt, 1 kg. Ethylene diaminetetraacetic acid.Dihydrate. Assay: 99.0-101.0%, nuclease-free.Risks: 36, 37, 38 ; Safety Precautions: 22, 36, 37. Category: Nucleotides & Enzymes & Biochemi...
Alkaline Phosphatase Stabilizer Solution, 1 L...
Biology Products: